C
1.18
-0.08 (-6.35%)
| Previous Close | 1.26 |
| Open | 1.26 |
| Volume | 2,555,326 |
| Avg. Volume (3M) | 231,314 |
| Market Cap | 79,739,440 |
| Price / Book | 0.740 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -1.78 |
| Total Debt/Equity (MRQ) | 0.25% |
| Current Ratio (MRQ) | 14.25 |
| Operating Cash Flow (TTM) | -29.18 M |
| Levered Free Cash Flow (TTM) | -16.14 M |
| Return on Assets (TTM) | -18.95% |
| Return on Equity (TTM) | -62.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Climb Bio, Inc. | Mixed | - |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | 0.75 |
|
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.07% |
| % Held by Institutions | 85.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (Baird, 662.71%) | Buy |
| 9.00 (HC Wainwright & Co., 662.71%) | Buy | |
| Median | 9.00 (662.71%) | |
| Low | 8.00 (BTIG, 577.97%) | Buy |
| Average | 8.67 (634.75%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 16 Oct 2025 | 8.00 (577.97%) | Buy | 1.95 |
| 30 Sep 2025 | 8.00 (577.97%) | Buy | 2.01 | |
| HC Wainwright & Co. | 13 Oct 2025 | 9.00 (662.71%) | Buy | 2.00 |
| Baird | 15 Aug 2025 | 9.00 (662.71%) | Buy | 1.90 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |